Table 2.
Strength of associations with YKL-40 immunohistochemical intensity.
| Association with YKL-40 IHC rank (P) |
|||
|---|---|---|---|
| Parameter | All gliomas | GBM only | AO only |
| Patient age | < 0.0001 | 0.0356 | 0.3953 |
| Gender | 0.0882 | 0.0684 | 0.9281 |
| Glioma type | < 0.0001 | NA | NA |
| Survival | 0.1612 | 0.8630 | 0.7131 |
| 1p19q codeletion | < 0.0001 | NA | 0.3097 |
| 9pL0H | 0.0602 | 0.0558 | 0.9493 |
| Homozygous CDKN2A deletion | 0.4536 | 0.7296 | 0.1328 |
| 10q23 LOH | 0.0006 | 0.8783 | 0.0276 |
| 17p13 LOH | 0.5380 | 0.0298 | 0.5023 |
| Ki67 (MIB-1) PI | 0.3723 | 0.3795 | 0.1141 |
| P53 accumulation | 0.6380 | 0.7702 | > 0.9999 |
| EGFR positive | 0.0034 | 0.0012 | 0.2361 |
| EGFR amplification | 0.3671 | 0.0054 | NA |
79 high grade gliomas were ranked according to YKL-40 expression via immunohistochemistry while blinded to all other clinical and pathologic variables (see Materials and Methods). Spearman rank correlations with key clinical and molecular features were then performed. AO = anaplastic oligodendroglioma; GBM = glioblas-toma; LOH = loss of heterozygosity; PI = proliferation index; NA = not applicable (none of the GBMs showed 1p19q codeletion and none of the AOs showed EGFR amplification).